Design of the RELAXin in acute heart failure study

American Heart Journal

Volumn 163, Issue 2, 2012, Pages

  Ponikowski, Piotr ^a   Metra, Marco ^b   Teerlink, John R ^c   Unemori, Elaine ^d   Felker, G Michael ^e   Voors, Adriaan A ^f   Filippatos, Gerasimos ^g   Greenberg, Barry ^h   Teichman, Sam L ^d   Severin, Thomas ⁱ   Mueller Velten, Guenther ⁱ   Cotter, Gad ^j   Davison, Beth A ^j  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b UNIVERSITY OF BRESCIA   (Italy)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Corthera Inc (A Novartis Company) ^*  (United States)

^e DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^f UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^g NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ NOVARTIS PHARMA AG   (Switzerland)

^j Momentum Research Inc   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RECOMBINANT RELAXIN; RECOMBINANT RELAXIN 2; RLX 030; UNCLASSIFIED DRUG;

ACUTE HEART FAILURE; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DYSPNEA; FOLLOW UP; HEART DEATH; HEART FAILURE; HOSPITAL READMISSION; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; VISUAL ANALOG SCALE;

EID: 84856541850     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2011.10.009     Document Type: Article

References (40)

1. M. Gheorghiade, and P.S. Pang Acute heart failure syndromes J Am Coll Cardiol 53 2009 557 573
2. L.W. Stevenson, A.S. Hellkamp, and C.V. Leier Changing preferences for survival after hospitalization with advanced heart failure J Am Coll Cardiol 52 2008 1702 1708
3. G. Cotter, H.C. Dittrich, and B.D. Weatherley The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment J Card Fail 14 2008 631 640
4. M. Metra, J.R. Teerlink, and G.M. Felker Dyspnoea and worsening heart failure in patients with acute heart failure: results from the Pre-RELAX-AHF study Eur J Heart Fail 12 2010 1130 1139
5. M. Metra, C.M. O'Connor, and B.D. Weatherley Early dyspnoea relief in acute heart failure: prevalence, association with mortality and effect of rolofylline in the PROTECT Study Eur Heart J 2011 In press
6. M. Gheorghiade, K.F. Adams, and J.G. Cleland Phase III clinical trial end points in acute heart failure syndromes: a virtual roundtable with the Acute Heart Failure Syndromes International Working Group Am Heart J 157 2009 957 970
7. G. Cotter, A.A. Voors, and B.D. Weatherley Acute Heart Failure Clinical Drug Development: from planning to proof of activity to phase III Cardiology 116 2010 292 301
8. M. Jessup, W.T. Abraham, and D.E. Casey 2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation Circulation 119 2009 1977 2016
9. K. Dickstein, A. Cohen-Solal, and G. Filippatos ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM) Eur J Heart Fail 10 2008 933 989
10. J.J. McMurray, and J.R. Teerlink Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials JAMA 298 2007 2009 2019 (Pubitemid 350074798)
11. J.G. Cleland, N. Freemantle, and A.P. Coletta Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE Eur J Heart Fail 8 2006 105 110 (Pubitemid 43012109)
12. M. Gheorghiade, M.A. Konstam, and J.C. Burnett Jr. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials JAMA 297 2007 1332 1343 (Pubitemid 46513234)
13. M.A. Konstam, M. Gheorghiade, and J.C. Burnett Jr. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial JAMA 297 2007 1319 1331 (Pubitemid 46513233)
14. B.M. Massie, C.M. O'Connor, and M. Metra Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure N Engl J Med 363 2010 1419 1428
15. J.D. Sackner-Bernstein, M. Kowalski, and M. Fox Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials JAMA 293 2005 1900 1905 (Pubitemid 40548187)
16. J.D. Sackner-Bernstein, H.A. Skopicki, and K.D. Aaronson Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure Circulation 111 2005 1487 1491 (Pubitemid 40470642)
17. A. Mebazaa, M.S. Nieminen, and M. Packer Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial JAMA 297 2007 1883 1891 (Pubitemid 46707842)
18. A.F. Hernandez, C.M. O'Connor, and R.C. Starling Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF) Circulation 122 2010 2217
19. X.J. Du, R.A. Bathgate, and C.S. Samuel Cardiovascular effects of relaxin: from basic science to clinical therapy Nat Rev Cardiol 7 2010 48 58
20. A. Jeyabalan, S.G. Shroff, and J. Novak The vascular actions of relaxin Adv Exp Med Biol 612 2007 65 87
21. T. Dschietzig, S. Teichman, and E. Unemori Intravenous recombinant human relaxin in compensated heart failure: a safety, tolerability, and pharmacodynamic trial J Card Fail 15 2009 182 190
22. K. Dickstein, A. Cohen-Solal, and G. Filippatos Corrigendum to ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008 [Eur Heart J 2008;29:2388-2442 and Eur J Heart Fail 2008;10:933-989]: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM) Eur J Heart Fail 11 2009 110
23. W.T. Abraham, K.F. Adams, and G.C. Fonarow In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE) J Am CollCardiol 46 2005 57 64 (Pubitemid 40905130)
24. U. Elkayam, M.W. Akhter, and H. Singh Comparison of effects on left ventricular filling pressure of intravenous nesiritide and high-dose nitroglycerin in patients with decompensated heart failure Am J Cardiol 93 2004 237 240 (Pubitemid 38058742)
25. A. Daiber, P. Wenzel, and M. Oelze New insights into bioactivation of organic nitrates, nitrate tolerance and cross-tolerance Clin Res Cardiol 97 2008 12 20
26. J.R. Teerlink, M. Metra, and G.M. Felker Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study Lancet 373 2009 1429 1439
27. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification Am J Kidney Dis 39 2 Suppl 1 2002 S1 266
28. M. Gheorghiade, L. De Luca, and G.C. Fonarow Pathophysiologic targets in the early phase of acute heart failure syndromes Am J Cardiol 96 2005 11G 17G
29. G.M. Felker, P.S. Pang, and K.F. Adams Clinical trials of pharmacological therapies in acute heart failure syndromes: lessons learned and directions forward Circ Heart Fail 3 2010 314 325
30. M. Gheorghiade, W.T. Abraham, and N.M. Albert Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure JAMA 296 2006 2217 2226 (Pubitemid 44708052)
31. M. Metra, J.G. Cleland, and B.D. Weatherley Dyspnoea in patients with acute heart failure: an analysis of its clinical course, determinants, and relationship to 60-day outcomes in the PROTECT pilot study Eur J Heart Fail 12 2010 499 507
32. M.S. Nieminen, D. Brutsaert, and K. Dickstein EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population Eur Heart J 27 2006 2725 2736 (Pubitemid 44729876)
33. S.A. Hunt, W.T. Abraham, and M.H. Chin Focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation J Am Coll Cardiol 53 2009 e1 e90
34. G.C. Fonarow, K.F. Adams Jr., and W.T. Abraham Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis JAMA 293 2005 572 580 (Pubitemid 40171239)
35. L.A. Danielson, O.D. Sherwood, and K.P. Conrad Relaxin is a potent renal vasodilator in conscious rats J Clin Invest 103 1999 525 533 (Pubitemid 29094053)
36. G.M. Felker, J.R. Teerlink, and P. Ponikowski The impact of time to treatment on vasodilator efficacy in acute heart failure: results from the Pre-RELAX-AHF study Eur J Heart Fail Suppl 8 2009 424
37. J.R. Teerlink, M. Metra, and A.A. Voors Increased symptom-improvement with the novel vasodilator, relaxin, in acute heart failure (AHF) patients with elevated blood pressure. Results from the Pre-RELAX-AHF study Eur Heart J Suppl 30 2009 164
38. CfMPfHU CHMP) Note for guidance on clinical investigation of medicinal products for the treatment of cardiac failure: addendum on acute cardiac failure 2005 European Medicines Agency
39. P.S. Pang, J.G. Cleland, and J.R. Teerlink A proposal to standardize dyspnoea measurement in clinical trials of acute heart failure syndromes: the need for a uniform approach Eur Heart J 29 2008 816 824 (Pubitemid 351431028)
40. L.A. Allen, M. Metra, and O. Milo-Cotter Improvements in signs and symptoms during hospitalization for acute heart failure follow different patterns and depend on the measurement scales used: an international, prospective registry to evaluate the evolution of measures of disease severity in acute heart failure (MEASURE-AHF) J Card Fail 14 2008 777 784